Related references
Note: Only part of the references are listed.Effectiveness of Oral Iron Chelator Treatment with Deferasirox in an Aceruloplasminemia Patient with a Novel Ceruloplasmin Gene Mutation
Yasuhiro Suzuki et al.
INTERNAL MEDICINE (2013)
Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin
Satoshi Kono et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment
Antonello Pietrangelo
GASTROENTEROLOGY (2010)
Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders
Yoshibumi Kaneko et al.
JOURNAL OF GASTROENTEROLOGY (2010)
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation
Armin Finkenstedt et al.
JOURNAL OF HEPATOLOGY (2010)
The neurological presentation of ceruloplasmin gene mutations
Alisdair McNeill et al.
EUROPEAN NEUROLOGY (2008)
Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea
Jong Wook Lee
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation
F. M. Skidmore et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Aceruloplasminemia: A novel mutation in a family with marked phenotypic variability
Alfonso Fasano et al.
MOVEMENT DISORDERS (2008)
Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin
Ivana De Domenico et al.
EMBO JOURNAL (2007)
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation
R Mariani et al.
GUT (2004)
Aceruloplasminemia:: new clinical, pathophysiological and therapeutic insights
O Loréal et al.
JOURNAL OF HEPATOLOGY (2002)
Share Paper
